Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National Cancer Database Analysis

医学 乳腺癌 内科学 肿瘤科 癌症 新辅助治疗 比例危险模型 病态的 阶段(地层学) 队列 古生物学 生物
作者
Guansheng Zhong,Dajiang Song,Weiyang Lou,Bajin Wei,Yaomin Chen,Hongwu Cui,Jingjing Hu,Huaying Dong,Jie Chen,Zhijun Dai
出处
期刊:Ejso [Elsevier BV]
卷期号:49 (11): 106970-106970 被引量:4
标识
DOI:10.1016/j.ejso.2023.06.022
摘要

Abstract

Background

The interest in breast cancer with low HER2 expression as a distinct subtype is increasing. We aimed to explore the differences between HER2-low and HER2-zero breast cancer in their prognosis and rate of pathological complete response (pCR) after neoadjuvant therapy.

Methods

The National Cancer Database (NCDB) was used to select patients with breast cancer who received neoadjuvant therapy from 2004 to 2017. Logistic regression model was constructed for analysis of pCR. Cox proportional hazards regression model and Kaplan–Meier method were used for survival analysis.

Results

A total of 41500 breast cancer patients were included, among which 14814 (35.7%) had HER2-zero tumors and 26686 (64.3%) had HER2-low. HER2-low tumors were more commonly HR-positive in comparison with HER2-zero (66.3% versus 47.1%, P < 0.001). A lower rate of pCR was observed in HER2-low tumors than in HER2-zero tumors after neoadjuvant therapy in the total cohort (OR = 0.90; 95% CI [0.86–0.95]; P < 0.001) and in the subset of HR-positive (OR = 0.87; 95% CI [0.81–0.94]; P < 0.001). Patients with HER2-low tumors had a significantly superior survival than those with HER2-zero tumors (HR = 0.90; 95% CI [0.86–0.94]; P < 0.001), regardless of the HR status. Additionally, a marginal survival difference was also observed between HER2 IHC1+ and HER2 IHC2+/ISH-negative (HR = 0.91; 95% CI [0.85–0.97]; P = 0.003) cohorts.

Conclusion

HER2-low tumors are a clinically relevant breast cancer subtype that is distinct from HER2-zero tumors. These findings may provide clues to appropriate therapeutic strategies for this subtype in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luckweb完成签到,获得积分10
2秒前
猫的毛完成签到 ,获得积分10
3秒前
nicky完成签到 ,获得积分10
4秒前
麦子完成签到 ,获得积分10
5秒前
5秒前
Wilson完成签到 ,获得积分10
6秒前
luckweb发布了新的文献求助10
6秒前
6秒前
10秒前
13秒前
传奇3应助wujiwuhui采纳,获得10
15秒前
开心寄松完成签到,获得积分10
17秒前
北宫完成签到 ,获得积分10
17秒前
wansida完成签到,获得积分10
21秒前
QXS完成签到 ,获得积分10
21秒前
22秒前
菠萝完成签到 ,获得积分10
22秒前
领导范儿应助Villanellel采纳,获得10
26秒前
wintersss完成签到,获得积分10
26秒前
尹尹发布了新的文献求助10
27秒前
量子星尘发布了新的文献求助10
29秒前
zzzzzz完成签到 ,获得积分10
33秒前
坦率的枕头完成签到,获得积分10
33秒前
XS_QI完成签到 ,获得积分10
33秒前
与共发布了新的文献求助10
36秒前
苑阿宇完成签到 ,获得积分10
36秒前
yck1027完成签到,获得积分10
37秒前
fatcat完成签到,获得积分10
37秒前
斯文败类应助Camus采纳,获得10
38秒前
40秒前
Tammy完成签到 ,获得积分10
40秒前
Herisland完成签到 ,获得积分10
42秒前
lulalula完成签到,获得积分10
43秒前
NEO完成签到 ,获得积分10
45秒前
zcydbttj2011完成签到 ,获得积分10
47秒前
温暖的小鸭子完成签到,获得积分10
49秒前
53秒前
王泽厚发布了新的文献求助20
54秒前
雪花发布了新的文献求助10
56秒前
周全完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022